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Despite the negative sensitivity test, when aprotinin was administered intravenously he developed a profound anaphylactic reaction with an unrecordable pulse rate and blood pressure. Active resuscitation by ventilation, massive fluid transfusion, and intravenous steroids was successful. After observation for 24 hours in the intensive care unit he was transferred to a surgical ward and discharged the next day.
Discussion
In our experience, injection of the pancreatic duct in patients undergoing endoscopic retrograde cholangiopancreatography is associated with hyperamylasaemia in 70% and acute pancreatitis in 21% of patients, patients with a history of pancreatitis being at particular risk. We therefore routinely intravenously administer the protease inhibitor aprotinin, in a bolus dose of 500 000 KIU, as prophylaxis immediately before the procedure. No reports have been published detailing the method and value of ocular pretesting for aprotinin sensitivity, but it is recommended by the manufacturer of the drug (Bayer UK Volumes of sputum were compared using standard analysis of variance (after a logarithmic transformation) and serum IgG concentrations using paired t test techniques. The figures reported for infections and time off work were not normally distributed and so were tested with a randomisation technique that is valid irrespective of the distribution of the values. This simulates the trial many times using the real data but assigns the four values for each patient at random, two to each treatment. The distribution of results that would have been observed if the allocation had been due solely to chance can then be used in assessing the actual result. 3 
Results
None of the 12 patients experienced reactions during or after the intravenous gammaglobulin infusions. For the five patients in the comparative trial the results for IgG concentrations, sputum volume, and infection scores were all significantly better, those for IgG concentrations highly so, during intravenous treatment than during intramuscular treatment (see table) . The scores for time off work showed no significant difference. There were no significant changes in forced expiratory volume or forced vital capacity after three months of intravenous treatment.
Both the serum IgG concentration (mean rise 2-3 g/l, range 1-6-3-2 g/l) and Clq concentration (rise 34%, range 5-80%) rose after treatment in six of the seven patients given fortnightly infusions of intravenous gammaglobulin. The exception was one patient who had a short half life for IgG. The concentrations of antitetanus toxoid antibodies changed rapidly during the first 48 hours after infusion of 6 g of intravenous gammaglobulin in these seven patients, probably because antibody was redistributed into the extravascular space. Once equilibrium had been established the half life of antibody in all butone patient was longer than two weeks.
Discussion
The health of five patients improved significantly when they received an intravenous gammaglobulin preparation every 18 days compared with weekly intramuscular gammaglobulin injections, probably because the intravenous regimen significantly increased the serum IgG concentrations. The design of the trial was not ideal, and the three monthly treatment periods were too short to be sure that any possible carryover effect was avoided. More definitive studies would require at least a two year trial with each treatment lasting for about six months.
The most common organism causing infection in patients deficient in antibodies is non-typable Haemophilus influenzae. Non-capsulated H influenzae will spontaneously bind Clq,4 and this may enhance opsonisation by activating the complement pathway. It is doubtful, however, whether patients with hypogammaglobulinaemia have Clq concentrations low enough to affect their predisposition to infection. Specific IgG antibody in the intravenous gammaglobulin used will opsonise H influenzae direct, and this is not greatly enhanced by additional complement activation.5
Suitable intravenous gammaglobulin preparations should be considered for patients with severe chest disease or the few patients who cannot tolerate the intramuscular injections because of pain or repeated reactions. Preparations with a half life of more than two weeks that contain opsonising antibodies to H influenzae are preferable. Fresh frozen plasma is a possible alternative, and the relative risks of transmitting hepatitis viruses by "small pool" plasma compared with "large pool" intravenous gammaglobulin can be ascertained only when intravenous treatment has been more extensively used.
